Heart Sounds Measurement Using the Wearable Cardioverter Defibrillator (HS-WCD) Study

Heart Failure Clinical Trial

Official title:

Heart Sounds Measurement Using the Wearable Cardioverter Defibrillator (HS-WCD): Study Protocol

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02825966
• Other study ID #: 90D0153
• Status: Completed
• Phase: N/A
• Start date: February 2016
• Est. completion date: March 2016

Study information

• Verified date: November 2020
• Source: Zoll Medical Corporation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A prospective, validation study to evaluate the data accuracy of heart sounds recorded by the LifeVest® Wearable Cardioverter Defibrillator (WCD). These data will be compared with the heart sounds data recorded by an FDA-cleared device AUDICOR AM device.

Description:

To conduct a prospective, validation study to evaluate the data accuracy of heart sounds recorded by the LifeVest® Wearable Cardioverter Defibrillator (WCD). To show equivalence, these data will be compared with the heart sounds data recorded by an FDA-cleared AUDCIOR AM device .

The study will enroll a minimum of 27 and a maximum of 35 subjects.

Participants will be adult patients (age ≥ 18 years) with at least seven patients over the age of 40 years. In addition, at least five patients with a history of heart failure will be included.

First, participants will wear the AUDICOR-AM device for 15 minutes while sitting quietly. Then, the AUDICOR device will be removed and the participants will wear the WCD for 15 minutes while sitting quietly. Next, while wearing the WCD, participants will perform various activities of daily living, including at least 6 hours of overnight wear. Finally, the WCD will be removed and the participants will wear the AUDICOR again for 15 minutes while sitting quietly.

This is a single center, prospective, observational study. This is a non-significant risk device study as all biological study parameters will be measured noninvasively with the WCD defibrillation capability disabled. In addition, the study device will not be used as a replacement for regularly prescribed therapies or diagnostics.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 35
• Est. completion date: March 2016
• Est. primary completion date: March 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Healthy male and female volunteers who are able to fit in the WCD garment (26 to 56 inches measured circumferentially at the level of the xiphoid process).

• Included in this group are at least five healthy subjects with a self-reported history of heart failure.

• The subject must be 18 years of age or older on the day of screening, with at least 7 subjects 40 years of age or older on the day of screening.

Exclusion Criteria:

• Mental, visual, physical, literacy, and auditory limitations that prevent interaction with the WCD equipment.

• Any acute medical conditions that prevent the following maneuvers: lying on back, lying on the right and left side, standing, sitting, and/ or leaning forward when sitting.

• Any self-reported shortness of breath, fatigue, swelling of feet, ankles, or legs, and/or chest pain

• Employees or family members of the sponsor.

• Unable or unwilling to provide written informed consent.

Related Conditions & MeSH terms

• Heart Failure

Intervention

Device:
• AUDICOR then LifeVest then AUDICOR
Wearable Cardioverter Defibrillator to record acoustic cardiograph signals.

Locations

Country	Name	City	State
United States	MedPace Phase 1 Clinic	Cincinnati	Ohio

Sponsors (1)

Lead Sponsor	Collaborator
Zoll Medical Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To Establish Equivalence Between the Heart Sounds Data Recorded by the LifeVest and FDA-cleared AUDICOR AM System.	Equivalence of the LifeVest device to the AUDICOR device was established by comparing the electromechanical activation time (EMAT) data of each device, collected during quiet sitting. The outcome was reported as the difference in EMAT measured by the LifeVest and AUDICOR device.	15 minutes of sitting for each group of measurements (Audicor device, then LifeVest, then Audicor device again).